Abstract 1995
Background
Anti-PD-1 and anti-CTLA-4 immunotherapies have become the standard of care for metastatic melanoma. However, the majority of patients develop resistance to therapy. Macrophages are abundant cells in tumours, but their role in immunotherapy response and resistance is largely unknown. This study investigated the role of macrophages in anti-PD-1 +/- CTLA-4 response in stage IV melanoma patients.
Methods
Transcriptomic and multiplex immunohistochemistry (mIHC) immune profiling were performed on formalin-fixed paraffin embedded tissue pre-treatment biopsies from advanced melanoma patients treated with anti-PD-1 (n = 19) or anti-PD-1 + anti-CTLA-4 (n = 10). Response and progression-free survival were assessed using RECIST criteria. Using tumour dissociates, mass cytometry was used to characterize macrophages in detail.
Results
Although there was no significant difference in CD68+ macrophages between responding and non-responding patients, responding patients had a significantly higher intratumoral density of CD14+ CD68+ CD16+ macrophages compared to non-responders at baseline (median= 192 versus 23; p = 0.006). Using mIHC, patients were classified into high/low CD16+ macrophages and differential RNA expression analysis was performed. CD16+ high macrophage tumours displayed increased expression of genes related to T cell activation (TIGIT, LAG3, ICOS, PDCD1, FASLG and TBX21), MHC class I presentation (TAP1, UBD, PSMB10 and B2M) and chemokine + cytokine activity (CXCL13, CXCL10, CXCL11, CXCL9, CXCR6 and CXCR3). Using mass cytometry, we determined that CD16+ macrophages are CD13+ HLA-DR+, ICOS+ CD86+/- LAG3- GITR- TIGIT-. Multivariate analysis showed that low LDH, low melanoma substage and the presence of high CD16+ macrophages were associated with a significantly better overall response rate (OR = 14; p = 0.011) and progression free survival (HR = 0.15; p = 0.016), but not overall survival (HR = 0.22; p = 0.068).
Conclusions
Presence of CD68+ CD14+ CD16+ macrophages in pre-treatment melanoma combined with low LDH and low melanoma substage strongly correlates with response and survival of advanced melanoma patients treated with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
James Wilmott.
Funding
National Health and Medical Research Council (NHMRC).
Disclosure
M.S. Carlino: Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract